• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Boehringer, Duke collaborate on IPF patient registry

Boehringer, Duke collaborate on IPF patient registry

August 26, 2016
CenterWatch Staff

Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute (DCRI) have announced the expansion of the Idiopathic Pulmonary Fibrosis—PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.

The IPF-PRO Registry, which was launched in June 2014, was the first multicenter longitudinal disease state registry in the U.S. focused specifically on IPF. Boehringer Ingelheim and the DCRI have agreed to expand the IPF-PRO Registry based on the quality of the data and insights obtained from the first 300 patients enrolled in the registry and the growing scientific need for diverse, real-world data to understand IPF disease progression, disease history, patient-reported outcomes and disease biomarkers.

"Expanding the IPF-PRO Registry is important to the IPF community because it will substantially advance the understanding of this rare and fatal lung disease," said Scott Palmer, M.D., director of Pulmonary Research at the DCRI. "In collecting data from a larger, more diverse group of patients from multiple centers nationwide—all of whom are newly diagnosed with IPF—this registry will allow us to better assess the impact of the disease over time on clinical and patient centered outcomes."

One element of the IPF-PRO Registry is a bio-repository that stores blood samples that provide patient genetic material that may help to better understand the relationship of various biomarkers to patient outcomes. The Registry expansion will substantially increase the size of the bio-repository, creating additional opportunities for future translational research and the identification of novel biomarkers that may be predictive of disease outcomes or individual patient treatment responses.

"The IPF-PRO Registry, which represents a valuable academic-industry partnership, is a substantial and important opportunity for Boehringer Ingelheim to contribute to the advancement of our understanding of IPF—independent of any particular medication or drug discovery effort," said Craig Conoscenti, M.D., principal expert, Clinical Development and Medical Affairs and Interstitial Lung Disease Program Lead, at Boehringer Ingelheim Pharmaceuticals. "We are proud to continue our collaborative partnership with the Duke Clinical Research Institute, as we bring our unique strengths and expertise together in working toward improving the lives of those living with IPF."

The centers that have been part of this successful registry to date include:

  • Cleveland Clinic, Dr. Daniel Culver
  • Duke University, Dr. Lake Morrison
  • Medical University of South Carolina, Dr. Timothy Whelan
  • National Jewish Health, Dr. Tristan Huie
  • Stanford University, Dr. Paul Mohabir
  • Temple University, Dr. Francis Cordova
  • Tulane University, Dr. Joseph Lasky
  • University of Alabama-Birmingham, Dr. Joao de Andrade
  • University of California-Los Angeles, Dr. John Belperio
  • University of Chicago, Dr. Imre Noth
  • University of Louisville, Dr. Jesse Roman
  • University of Michigan, Dr Kevin Flaherty
  • University of Minnesota, Dr. Hyun Kim
  • University of Texas Southwestern Medical Center, Dr. John Fitzgerald
  • Vanderbilt University, Dr. Lisa Lancaster
  • Weill Cornell Medical College
  • Yale University, Dr. Mridu Gulati

IPF is a rare and serious lung disease that causes permanent scarring of the lungs. It affects as many as 132,000 Americans, typically men over the age of 65. Early diagnosis and proper care are critical to helping people treat their condition.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing